地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18995651644
传真:18327026838
邮箱:sales@amyjet.com

艾美捷科技特约代理Bio X Cell抗体产品。
Bio X Cell位于美国Lebanon, New Hampshire,专注于为生物医药领域制造从毫克到克级的高品质单克隆抗体。
Bio X Cell specializes in manufacturing high quality, bulk quantity (milligram to gram) monoclonal antibodies for biomedical research. All our products are manufactured in the United States in our Lebanon, New Hampshire facility. At Bio X Cell we strive to provide scientists with ultra-pure antibodies targeting both well-characterized and novel antigens in the large quantities required for in vivo preclinical studies. We aim to facilitate the advancement of scientific discovery and innovation by providing our products at outstanding prices and backing them up with exceptional customer and technical support.
Bio X Cell的主要抗体包括:
(1)按CELL TYPE分为
T Cells
B Cells
NK Cells
Neutrophils
Monocytes & Macrophages
Dendritic Cells
(2)按AREA OF RESEARCH分为
Immunology
Innate Immunity
Cancer Biology
Immune Checkpoint Proteins
Cytokines and Chemokines
Cytokine Receptors
Cell Migration & Adhesion
Apoptosis
" data-original="http://haemtech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技特约代理Bio X Cell抗体产品"> 艾美捷科技特约代理Bio X Cell抗体产品
Trevigen致力于为研究人员提供高品质的试剂和试剂盒,用于细胞程序性死亡、DNA损伤和修复的研究。在过去的十年里,对于凋亡的研究越来越多,然而直到最近才开始将凋亡与DNA损伤联系在一起,并给予极大的关注。Trevigen能够为这一新兴领域提供高水平的产品和支持。而基于Trevigen在肿瘤研究产品核心业务的自然延伸,Trevigen开发出了一系列用于研究肿瘤细胞功能和行为的产品,包括血管生成、细胞侵袭、浸润和肿瘤形成等产品和试剂盒。所有Trevigen品牌的产品均基于最高质量标准生产,并被给予最强有力的技术支持。
Trevigen, Inc. is an innovative biotechnology company focused on the development of products and technology for cancer research and genetic toxicology, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. The company is located in the I-270 “Technology Corridor” in Gaithersburg, Maryland. Trevigen-brand research products are marketed via the Internet, journal advertising, direct mail, and telemarketing, giving Trevigen worldwide recognition among those in the area of cancer research. Distributor appointments have been made in the Americas, Europe, and the Pacific Rim. Trevigen also has in place supply agreements with major government and university medical research centers in order to make us a part of the growing areas of government research and pharmaceutical research. The company is the recipient of several SBIR grants from the National Institutes of Health, concerning technology development for the analysis of DNA damage.
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://haemtech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Trevigen"> Trevigen
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://haemtech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

艾美捷科技特约代理Cell Biolabs公司产品。
Cell Biolabs公司一直致力于开发生命科学研究领域的技术和工具,并将所开发的创新性技术成果商业化。我们孜孜不倦专注于提供最完善的产品,以期使细胞功能和疾病机制研究领域达到新高度。
Cell Biolabs, Inc. proudly develops and commercializes innovative technologies and tools for life science research. We are committed to providing the best products that facilitate discovery of the mechanisms underlying cell function and disease. Our unique, cutting-edge products are currently used around the world in the research laboratories of universities, government institutes, biotechnology and pharmaceutical companies.
Cell Biolabs公司的主要产品包括:
细胞分析
病毒表达和纯化试剂
氧化应激分析
小G蛋白分析试剂盒和试剂
按照研究领域细分:
Cell Based Assays
Pathogen & Toxin Assays
Cell Signaling & Protein Biology
Stem Cell Research
Metabolism Research
Viral Expression
Oxidative Stress / Damage
Frequently Asked Questions about Cell Biolabs Products
" data-original="http://haemtech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技特约代理Cell Biolabs公司产品"> 艾美捷科技特约代理Cell Biolabs公司产品
Anogen-Yes Biotech Laboratories Ltd. 创建于1989年, 位于加拿大多伦多近郊的著名高科技城市密西沙加市。Anogen是加拿大逸士生物技术研究有限公司在国际上的市场经销部门。Anogen-Yes Biotech Laboratories Ltd.研发和生产各种新颖抗体及有关产品,应用广泛的技术平台设计和开发各种单克隆抗体、多克隆抗体、基因工程/人源化抗体、免疫检验用配对抗体、免疫球蛋白、活性多肽、酶联免疫试剂盒[ELISA]、斑点酶联免疫试剂盒[Elispots]和基因重组蛋白质等等。 这些产品主要用于生命科学研究和各种疾病的诊断和防治,包括炎症和自身免疫性疾病、心血管病和癌症等。
Anogen is the trade name of Yes Biotech Laboratories Ltd., a Canadian biopharmaceutical company based in Mississauga, Ontario. Founded in 1989, Anogen-Yes Biotech specializes in developing and manufacturing monoclonal antibodies, recombinant proteins, synthetic bioactive peptides, and Enzyme linked immunosorbent assay (ELISA) kits for research as well as diagnostic and therapeutic use.[1] It is also committed to seeking medical treatment of cancer, autoimmune, inflammatory and cardiovascular diseases by developing antibody-based biopharmaceuticals.
Anogen的主要产品包括:
Monoclonal Antibodies
Polyclonal Antibodies
Matched Antibody Pairs
ELISA Kits
按照研究领域细分:
Inflammatory & Growth Factors
Cell Biology & Molecular Biology
Immunoassay Reagents
Infection & Toxin
Coagulation Factors
Hormone
Neurological Disorder
Tumor Research
| 品名 | 货号 | 规格 |
| mAb anti-Human TNF-α, CH8810 | MO-C40003A | 0.1 mg |
| mAb anti-Human TNF-α, CH8820, Capture | MO-C40003B | 0.1 mg |
| mAb anti-Human TNF-α, C2H9 | MO-C40003D | 0.1 mg |
| mAb anti-Human TNF-α, B1E4, Detector | MO-C40003E | 0.1 mg |
| mAb anti-Human TNF-α, C2A7 | MO-C40003F | 0.1 mg |
| mAb anti-Human TNF-α, C5G7 | MO-C40003G | 0.1 mg |
| mAb anti-Human TNF-α, C4C7 | MO-C40003H | 0.1 mg |
| mAb anti-Human IFN-γ, 315 | MO-C40004D | 0.1 mg |
| mAb anti-Human IFN-γ, 165 | MO-C40004E | 0.1 mg |
| mAb anti-Human IFN-γ, 23 | MO-C40004F | 0.1 mg |
| mAb anti-Human CCR1, 293 | MO-C40005A | 0.1 mg |
| mAb anti-Human TGF-β, TB21 | MO-C40009A | 0.1 mg |
| mAb anti-Human TGF-β, 2C5 | MO-C40009B | 0.1 mg |
| mAb anti-Human TGF-β, 2C6 | MO-C40009D | 0.1 mg |
| mAb anti-Human TGF-β, 2E6 | MO-C40009E | 0.1 mg |
| mAb anti-Human TGF-β, 8C4 | MO-C40009F | 0.1 mg |
| mAb anti-Human IL-8, I8-S2, Capture | MO-C40017A | 0.1 mg |
| mAb anti-Human IL-8, I8-60, Detector | MO-C40017D | 0.1 mg |
| mAb anti-Human IL-8, I8-61 | MO-C40017E | 0.1 mg |
| mAb anti-Human IL-8, 257 | MO-C40017F | 0.1 mg |
| mAb anti-Human IL-8, 807 | MO-C40017G | 0.1 mg |
| mAb anti-Human MCP-1, S8 | MO-C40021A | 0.1 mg |
| mAb anti-Human MCP-1, S14, Capture | MO-C40021B | 0.1 mg |
| mAb anti-Human MCP-1, S101, Detector | MO-C40021D | 0.1 mg |
| mAb anti-Human MCP-1, 9G10 | MO-C40021E | 0.1 mg |
| mAb anti-Human MCP-1, S382 | MO-C40021F | 0.1 mg |
| mAb anti-Human SAA, 115, Capture | MO-C40028A | 0.1 mg |
| mAb anti-Human SAA, 513 | MO-C40028D | 0.1 mg |
| mAb anti-Human SAA, 607, Detector | MO-C40028E | 0.1 mg |
| mAb anti-Human SAA, 291 | MO-C40028G | 0.1 mg |
| mAb anti-Human SAA, 504 | MO-C40028H | 0.1 mg |
| mAb anti-Human SAA, 585 | MO-C40028J | 0.1 mg |
| mAb anti-Human SAA, 426 | MO-C40028K | 0.1 mg |
| mAb anti-Human SAA, 38 | MO-C40028L | 0.1 mg |
| mAb anti-Human SAA, 132 | MO-C40028M | 0.1 mg |
| mAb anti-Human SAA, S3 | MO-C40028N | 0.1 mg |
| mAb anti-Human IL-1β, S1H12 | MO-C40029A | 0.1 mg |
| mAb anti-Human IL-1β, S1B7 | MO-C40029B | 0.1 mg |
| mAb anti-Human IL-1β, S3F12 | MO-C40029G | 0.1 mg |
| mAb anti-Human IL-1β, 464 | MO-C40029H | 0.1 mg |
| mAb anti-Human IL-2, 5A8, | MO-C40032A | 0.1 mg |
| mAb anti-Human IL-2, 9F9, | MO-C40032B | 0.1 mg |
| mAb anti-Human IL-2, 10C4 | MO-C40032C | 0.1 mg |
| mAb anti-Human IL-2, 8C2 | MO-C40032D | 0.1 mg |
| mAb anti-Human IL-2, 6F11 | MO-C40032E | 0.1 mg |
| mAb anti-Human IL-2, 6B1 | MO-C40032F | 0.1 mg |
| mAb anti-Human EGF, S-21 | MO-C40044A | 0.1 mg |
| mAb anti-Human EGF, S-120 | MO-C40044B | 0.1 mg |
| mAb anti-Human EGF, S-134, Capture | MO-C40044D | 0.1 mg |
| mAb anti-Human EGF, S-145 | MO-C40044E | 0.1 mg |
| mAb anti-Human EGF, S-146, Detector | MO-C40044F | 0.1 mg |
| mAb anti-Human EGF, S-147 | MO-C40044G | 0.1 mg |
| mAb anti-Human EGF, S-177 | MO-C40044H | 0.1 mg |
| mAb anti-Human G-CSFR, S-1252 | MO-C40045A | 0.1 mg |
| mAb anti-Human G-CSFR, S-1268 | MO-C40045B | 0.1 mg |
| mAb anti-Human G-CSFR, S-1284 | MO-C40045D | 0.1 mg |
| mAb anti-Human G-CSFR, S-1374 | MO-C40045E | 0.1 mg |
| mAb anti-Human G-CSFR, S-425 | MO-C40045F | 0.1 mg |
| mAb anti-Human G-CSFR, S-1390 | MO-C40045G | 0.1 mg |
| mAb anti-Human bFGF, F-343 | MO-C40046A | 0.1 mg |
| mAb anti-Human bFGF, F-74 | MO-C40046B | 0.1 mg |
| mAb anti-Human bFGF, F-474 | MO-C40046F | 0.1 mg |
| mAb anti-Human bFGF, F-3 | MO-C40046H | 0.1 mg |
| mAb anti-Human EPO, 85 | MO-C40047A | 0.1 mg |
| mAb anti-Human M-CSF, 116 | MO-C40048A | 0.1 mg |
| mAb anti-Human M-CSF, 692 | MO-C40048B | 0.1 mg |
| mAb anti-Human M-CSF, 21 | MO-C40048D | 0.1 mg |
| mAb anti-Human MIP-1α, 116 | MO-C40051A | 0.1 mg |
| mAb anti-Human MIP-1α, 125 | MO-C40051D | 0.1 mg |
| mAb anti-Human MIP-1α, 548 | MO-C40051F | 0.1 mg |
| mAb anti-Human MIP-1α, 199 | MO-C40051G | 0.1 mg |
| mAb anti-Human MIP-1α, 400 | MO-C40051L | 0.1 mg |
| mAb anti-Human MIP-1α, 103 | MO-C40051M | 0.1 mg |
| mAb anti-Human MIP-1α, 376 | MO-C40051N | 0.1 mg |
| mAb anti-Human MIP-1α, 426 | MO-C40051P | 0.1 mg |
| mAb anti-Human MCP-3, 113, Detector | MO-C40088A | 0.1 mg |
| mAb anti-Human MCP-3, 343 | MO-C40088B | 0.1 mg |
| mAb anti-Human MCP-3, 490 | MO-C40088D | 0.1 mg |
| mAb anti-Human MCP-3, 768 | MO-C40088E | 0.1 mg |
| mAb anti-Human MCP-3, 1057 | MO-C40088F | 0.1 mg |
| mAb anti-Human MCP-3, 542, Capture | MO-C40088G | 0.1 mg |
| mAb anti-Human MCP-3, 1015 | MO-C40088H | 0.1 mg |
| mAb anti-Human IL-16, 59 | MO-C40089G | 0.1 mg |
| mAb anti-Human IL-16, 210 | MO-C40089H | 0.1 mg |
| mAb anti-Human IL-16, 323, Detector | MO-C40089J | 0.1 mg |
| mAb anti-Human IL-16, 398, Capture | MO-C40089K | 0.1 mg |
| mAb anti-Human IL-16, 568 | MO-C40089M | 0.1 mg |
| mAb anti-Human IL-16, 572 | MO-C40089N | 0.1 mg |
| mAb anti-Human GM-CSF, 29 | MO-C40090A | 0.1 mg |
| mAb anti-Human GM-CSF, 59, Capture | MO-C40090B | 0.1 mg |
| mAb anti-Human GM-CSF, 429, Detector | MO-C40090D | 0.1 mg |
| mAb anti-Human GM-CSF, 204 | MO-C40090E | 0.1 mg |
| mAb anti-Human GM-CSF, 489 | MO-C40090F | 0.1 mg |
| mAb anti-Human GM-CSF, 120 | MO-C40090G | 0.1 mg |
| mAb anti-Human GM-CSF, 26 | MO-C40090H | 0.1 mg |
| mAb anti-Human GM-CSF, 174 | MO-C40090K | 0.1 mg |
| mAb anti-Human GM-CSF, S333 | MO-C40090L | 0.1 mg |
| mAb anti-Human IL-6, 2E10 | MO-C40091B | 0.1 mg |
| mAb anti-Human IL-6, 8E10 | MO-C40091C | 0.1 mg |
| mAb anti-Human IL-6, 5G8 | MO-C40091D | 0.1 mg |
| mAb anti-Human IL-6, 1B6 | MO-C40091E | 0.1 mg |
| mAb anti-Human IL-6, 1E3 | MO-C40091F | 0.1 mg |
| mAb anti-Human IL-6, 6D7 | MO-C40091G | 0.1 mg |
| mAb anti-Human IL-6, 9D8 | MO-C40091H | 0.1 mg |
| mAb anti-Human IL-10, 4H2 | MO-C40092A | 0.1 mg |
| mAb anti-Human IL-10, 6D2 | MO-C40092B | 0.1 mg |
| mAb anti Human IL-17A clone 4C1, Capture | MO-C40093A | 0.1mg |
| mAb anti Human IL-17A clone 2F3 | MO-C40093B | 0.1mg |
| mAb anti Human IL-17A clone 8H7 | MO-C40093C | 0.1mg |
| mAb anti Human IL-17A clone 5B4 | MO-C40093D | 0.1mg |
| mAb anti Human IL-17A clone 1E2 | MO-C40093E | 0.1mg |
| mAb anti Human IL-17A clone 2D11 | MO-C40093H | 0.1mg |
| mAb anti Human IL-17A clone 3C1 | MO-C40093I | 0.1mg |
| mAb anti Human IL-17A clone 3H11, Detector | MO-C40093K | 0.1mg |
| mAb anti Human IL-17A clone 5A9 | MO-C40093M | 0.1mg |
| mAb anti Human IL-17A clone 6F12 | MO-C40093O | 0.1mg |
| mAb anti Human IL-17A clone 7F10 | MO-C40093S | 0.1mg |
| mAb anti Human IL-17A clone 10F9 | MO-C40093W | 0.1mg |
| mAb anti Human IL-18 clone 2A10, Capture | MO-C40094A | 0.1mg |
| mAb anti Human IL-18 clone 10H4, Detector | MO-C40094B | 0.1mg |
| mAb anti human IL-18 clone 10H4, Tracer (Biotin Labeled) | MO-C40094TB | 0.1 mL |
| mAb anti Human IL-15 clone 5E8, Capture | MO-C40095A | 0.1mg |
| mAb anti Human IL-15 clone B1H6, Detector | MO-C40095B | 0.1mg |
| mAb anti-human LIF, Clone 2C6 | MO-C40096A | 0.1mg |
| mAb anti-human LIF, Clone 3F4 | MO-C40096B | 0.1mg |
| mAb anti-human LIF, Clone 8B10 | MO-C40096C | 0.1mg |
| mAb anti-DYKDDDDK (Flag) Tag, Flag.10F4 | MO-H40001B | 0.1 mg |
| mAb anti-GAPDH, H8 | MO-H40002A | 0.1 mg |
| mAb anti-HA Tag, HA52 | MO-H40004A | 0.1 mg |
| mAb anti-His Tag, 10A12 | MO-H40005B | 0.1 mg |
| mAb anti-Myc Tag, MycA7 | MO-H40006A | 0.1 mg |
| mAb anti-V5 Tag, V531 | MO-H40007A | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 473, Detector | MO-I40002A | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 163 | MO-I40002C | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 340, Capture | MO-I40002D2 | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 587, 0.1 mg | MO-I40002E | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 425 | MO-I40002I | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 1027 | MO-I40002J | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 287 | MO-I40002N | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 161 | MO-I40002P | 0.1 mg |
| mAb anti-HBsAg, RM-1 | MO-I40013A | 0.1 mg |
| mAb anti-HCV Core Protein, A1/3D1 | MO-I40015A | 0.1 mg |
| mAb anti-HCV Core Protein, B2 | MO-I40015B | 0.1 mg |
| mAb anti-HCV Core Protein, C3 | MO-I40015E | 0.1 mg |
| mAb anti-HCV NS-4, 7B7/5G9 | MO-I40016B | 0.1 mg |
| mAb anti-HCV NS-4, 5D4/10E7 | MO-I40016D | 0.1 mg |
| mAb anti-HCV NS-4, 7E11 | MO-I40016F | 0.1 mg |
| mAb anti-HCV NS-4, 202 | MO-I40016J | 0.1 mg |
| mAb anti-HCV NS-4, 101 | MO-I40016K | 0.1 mg |
| mAb anti-HCV NS-4, 174 | MO-I40016L | 0.1 mg |
| mAb anti-HCV NS-4, 497 | MO-I40016M | 0.1 mg |
| mAb anti-HCV NS-3, 70-13 | MO-I40018A | 0.1 mg |
| mAb anti-HCV NS-3, 1-5 | MO-I40018B | 0.1 mg |
| mAb anti-HCV NS-3, 12-15 | MO-I40018D | 0.1 mg |
| mAb anti-HCV NS-3, 5-11 | MO-I40018E | 0.1 mg |
| mAb anti-HCV NS-3, 24-8 | MO-I40018F | 0.1 mg |
| mAb anti-HCV NS-3, 20-8 | MO-I40018G | 0.1 mg |
| mAb anti-HCV NS-3, 113 | MO-I40018H | 0.1 mg |
| mAb anti-HCV NS-3, 281 | MO-I40018J | 0.1 mg |
| mAb anti-HCV NS-3, 806 | MO-I40018K | 0.1 mg |
| mAb anti-HCV NS-3, 5 | MO-I40018L | 0.1 mg |
| mAb anti-HCV NS-3, 328 | MO-I40018M | 0.1 mg |
| mAb anti-HCV NS-3, 251 | MO-I40018N | 0.1 mg |
| mAb anti-HCV NS-3, 242 | MO-I40018P | 0.1 mg |
| mAb anti-HCV NS-3, 133 | MO-I40018Q | 0.1 mg |
| mAb anti-HEV, S-13 | MO-I40019B | 0.1 mg |
| mAb anti-HEV, 4H5 | MO-I40019C | 0.1 mg |
| mAb anti-HEV, 2H6 | MO-I40019D | 0.1 mg |
| mAb anti-HEV, 2H2 | MO-I40019E | 0.1 mg |
| mAb anti-HEV, 1B6 | MO-I40019F | 0.1 mg |
| mAb anti-HEV, 5H4 | MO-I40019G | 0.1 mg |
| mAb anti-HP CagA, 10E9, | MO-I40020A | 0.1 mg |
| mAb anti-HP CagA, 5H10 | MO-I40020B | 0.1 mg |
| mAb anti-HP CagA, 5C6 | MO-I40020C | 0.1 mg |
| mAb anti-HP CagA, 3C10, | MO-I40020D | 0.1 mg |
| mAb anti-HP CagA, 3C1 | MO-I40020E | 0.1 mg |
| mAb anti-TB 38KD Antigen, D2G2 | MO-I40021A | 0.1 mg |
| mAb anti-TB 38KD Antigen, C12H11 | MO-I40021B | 0.1 mg |
| mAb anti-TB 38KD Antigen, C11B10 | MO-I40021C | 0.1 mg |
| mAb anti-TB 38KD Antigen, B12F8 | MO-I40021D | 0.1 mg |
| mAb anti-TB 38KD Antigen, A11D2 | MO-I40021E | 0.1 mg |
| mAb anti-TB 38KD Antigen, A2H8 | MO-I40021F | 0.1 mg |
| mAb anti-Human CD3, JXT3 | MO-L40001A | 0.1 mg |
| Rat anti-Mouse CD4, JXYT4 | MO-L40026 | 0.1 mg |
| Rat anti-Mouse CD8, JXYT8 | MO-L40027 | 0.1 mg |
| mAb anti-Human CD11α, A11 | MO-L40028 | 0.1 mg |
| mAb anti-Human HLA-ABC, LY5.1 | MO-L40033 | 0.1 mg |
| mAb anti-Human CD71 Transferrin Receptor, CY-TFR | MO-L40042 | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 1C4 | MO-L40043A | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 7C9, Capture | MO-L40043B | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 9E11 | MO-L40043E | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 9B4 | MO-L40043F | 0.1 mg |
| mAb anti-Human PD-1 / CD279, B1C4 | MO-L40043G | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 7G12, Detector | MO-L40043L | 0.1 mg |
| mAb anti-Human PD-1 / CD279, 2H7 | MO-L40043M | 0.1 mg |
| mAb anti Human PD-L1, clone 6A5 | MO-L40044E | 0.1 mg |
| mAb anti Human PD-L1 clone 8C12 | MO-L40044F | 0.1 mg |
| mAb anti Human PD-L1 clone 12B4, Detector | MO-L40044I | 0.1 mg |
| mAb anti Human PD-L1 clone 11D11 | MO-L40044M | 0.1 mg |
| mAb anti Human PD-L1 clone 15G3, Capture | MO-L40044N | 0.1 mg |
| mAb anti Human PD-L1 clone 12D9 | MO-L40044O | 0.1 mg |
| mAb anti Human PD-L1 clone 15F2 | MO-L40044R | 0.1 mg |
| mAb anti Human PD-L1, clone 10B12 | MO-L40044S | 0.1 mg |
| mAb anti Human CD47, clone 1G10 | MO-L40045A | 0.1 mg |
| mAb anti Human CD47, clone 8H7 | MO-L40045B | 0.1 mg |
| mAb anti Human CD47, clone 9F10 | MO-L40045C | 0.1 mg |
| mAb anti Human CD44, clone 2G7 | MO-L40046A | 0.1 mg |
| mAb anti Human CD44, clone 3C7 | MO-L40046B | 0.1 mg |
| mAb anti-hCG-α, CH5 | MO-M40010A | 0.1 mg |
| mAb anti-hCG-α, CH7 | MO-M40010B | 0.1 mg |
| mAb anti-TRICHOSANTHIN (TCST), TCST-1, 0.1 mg | MO-M40011A | 0.1 mg |
| mAb anti-hGH, YC6, Capture | MO-M40012A | 0.1 mg |
| mAb anti-Human Ig Kappa Light Chain, YCK1 | MO-M40020 | 0.1 mg |
| mAb anti-Human B2MG, D6E4 | MO-M40021B | 0.1 mg |
| mAb anti-Human B2MG, D2E9, Capture | MO-M40021C | 0.1 mg |
| mAb anti-Human B2MG, D6D1 | MO-M40021D | 0.1 mg |
| mAb anti-Human B2MG, D2A10 | MO-M40021E | 0.1 mg |
| mAb anti-Human B2MG, D3A2, Detector | MO-M40021F | 0.1 mg |
| mAb anti-human CRP, 63F4, Capture | MO-M40023A | 0.1 mg |
| mAb anti-human CRP, 67A1 | MO-M40023B | 0.1 mg |
| mAb anti-human CRP, N1G1 | MO-M40023D | 0.1 mg |
| mAb anti-human CRP, S5G1 | MO-M40023E | 0.1 mg |
| mAb Rat anti-Aflatoxin, 1C6, 0.1 mg | MO-M40025A | 0.1 mg |
| mAb Rat anti-Aflatoxin, 1E6, 0.1 mg | MO-M40025B | 0.1 mg |
| mAb Rat anti-Aflatoxin, 2E4 | MO-M40025D | 0.1 mg |
| mAb anti-Human Albumin, S4D6 | MO-M40036 | 0.1 mg |
| mAb anti-Human Factor IX, F9-1, .01 mg | MO-M40037 | 0.1 mg |
| mAb anti-Human Protein C, HLW-C, 0.1 mg | MO-M40038 | 0.1 mg |
| mAb anti-Human Factor X, F10-1, 0.1 mg | MO-M40039 | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 237, 0.1 mg | MO-M40040A | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 474, 0.1 mg | MO-M40040B | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, Y8 | MO-M40040D | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 700 | MO-M40040E | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 585 | MO-M40040F | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 8 | MO-M40040H | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 291 | MO-M40040J | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 262 | MO-M40040N | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 71 | MO-M40040Q | 0.1 mg |
| mAb anti-Human GP IIb/IIIa, 128 | MO-M40040S | 0.1 mg |
| mAb anti-Staphylococcal Enterotoxin B [SEB], 0.1 mg | MO-M40041 | 0.1 mg |
| mAb anti-Human PTP1-C, PTY6 | MO-M40043A | 0.1 mg |
| mAb anti-Human PTP1-C, PTY11 | MO-M40043B | 0.1 mg |
| mAb anti-Human PTP1-C, PTY15 | MO-M40043D | 0.1 mg |
| mAb anti-Human PTP1-C, PTY10 | MO-M40043E | 0.1 mg |
| mAb anti-Human PTP1-C, PTY13 | MO-M40043F | 0.1 mg |
| mAb anti-human TSH, TSH-2, Detector | MO-M40046A | 0.1 mg |
| mAb anti-human TSH, TSH-1, Capture | MO-M40046B | 0.1 mg |
| mAb anti-Human Prolactin, PRL-1, Capture | MO-M40047B | 0.5 mg |
| mAb anti-Human LH, LH-1, Capture | MO-M40048B | 0.5 mg |
| mAb anti-hCG, HCG-1, Capture | MO-M40049B | 0.5 mg |
| mAb anti-Human FSH, FSH-1, Capture | MO-M40050B | 0.5 mg |
| mAb anti-Human Raf-1, 410 | MO-M40091E | 0.5 mg |
| mAb anti-Human Raf-1, 540 | MO-M40091G | 0.5 mg |
| mAb anti-Human Raf-1, 863 | MO-M40091J | 0.5 mg |
| mAb anti-Human Raf-1, 163 | MO-M40091M | 0.5 mg |
| mAb anti-Human NSE, 145 | MO-M40092A | 0.5 mg |
| mAb anti-Human NSE, 1G6 | MO-M40092B | 0.5 mg |
| mAb anti-Human NSE, 171 | MO-M40092C | 0.5 mg |
| mAb anti-Amyloid β Peptide 42, CA9 3B3 | MO-M40093A | 0.1 mg |
| mAb anti-Amyloid β Peptide 42, CA9 10C11, Detector | MO-M40093B | 0.5 mg |
| mAb anti-Amyloid β Peptide 42, CA9 3F8 | MO-M40093D | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 3F5 | MO-M40094A | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 1H3 | MO-M40094B | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 6C8 | MO-M40094C | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 5B8, Capture | MO-M40094D | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 4A2 | MO-M40094E | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 7H7 | MO-M40094F | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 5A4 | MO-M40094G | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 4B7 | MO-M40094H | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 7G10 | MO-M40094I | 0.5 mg |
| mAb anti-Amyloid β Peptide N-terminal, NT 1F10 | MO-M40094J | 0.5 mg |
| mAb anti-Amyloid β Peptide 40, CV9 7B10, Detector | MO-M40095A | 0.1 mg |
| mAb anti-Amyloid β Peptide 40, CV9 8B2 | MO-M40095B | 0.1 mg |
| mAb anti-Amyloid β Peptide 40, 4B1 | MO-M40095C | 0.1 mg |
| mAb anti-Human α1-antitrypsin, 5G5 | MO-M40096A | 0.1 mg |
| mAb anti-Human α1-antitrypsin, 9F2 | MO-M40096B | 0.1 mg |
| mAb anti-Human α-Synuclein, 4H11 | MO-M40097A | 0.1 mg |
| mAb anti-Human α-Synuclein, 4C1 | MO-M40097B | 0.1 mg |
| mAb anti-Human α-Synuclein, 4B4 | MO-M40097C | 0.1 mg |
| mAb anti-Human α-Synuclein, 8F12 | MO-M40097D | 0.1 mg |
| mAb anti-Human α-Synuclein, 9A9 | MO-M40097E | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, 3E11 | MO-M40098A | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B2B3 | MO-M40098B | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B4H12 | MO-M40098C | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B5B11 | MO-M40098D | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B7B10 | MO-M40098E | 0.1 mg |
| mAb anti-Human α1-antichymotrypsin, B7H2 | MO-M40098F | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 1A4 | MO-M40099A | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 7G9 | MO-M40099B | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 9B4 | MO-M40099C | 0.1 mg |
| mAb anti-Thr181 Phosphorylated Tau, 2A4 | MO-M40099D | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 8E1 | MO-M40100A | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 1G8 | MO-M40100B | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 4C1 | MO-M40100C | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 3B12 | MO-M40100D | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 4H1 | MO-M40100E | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 4H11 | MO-M40100F | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 5C11 | MO-M40100G | 0.1 mg |
| mAb anti-human Thr212 Thr217 double phosphorylated Tau, 10G9 | MO-M40100H | 0.1 mg |
| mAb anti-LCRMP4, 5H5 | MO-M40101A | / |
| mAb anti-LCRMP4, 2H7 | MO-M40101B | / |
| mAb anti-LCRMP4 , 7E1 | MO-M40101C | / |
| mAb anti-Human Phospho-STAT5b [p-Y699], A4B9 | MO-P40001A | 0.1 mg |
| mAb anti-Human Phospho-STAT5b [p-Y699], A2H6 | MO-P40001B | 0.1 mg |
| mAb anti-Human Phospho-ELK-1 [p-S383], B4A12 | MO-P40002A | 0.1 mg |
| mAb anti-Human Phospho-ELK-1 [p-S383], D7H2 | MO-P40002B | 0.1 mg |
| mAb anti-Human Phospho-CREB [p-S133], A3A4 | MO-P40003A | 0.1 mg |
| mAb anti-Human Phospho-CREB [p-S133], B1C4 | MO-P40003B | 0.1 mg |
| mAb anti-Human FPRL-1 C-terminal, C4F9 | MO-P40006A | 0.1 mg |
| mAb anti-Human FPRL-1 C-terminal, B4D9B10 | MO-P40006B | 0.1 mg |
| mAb anti-Human FPRL-1 2nd extracellular loop, 3D7 | MO-P40007A | 0.1 mg |
| mAb anti-Human FPRL-1 2nd extracellular loop, B7H10 | MO-P40007B | 0.1 mg |
| mAb anti-Human Lung Carcinoma, CHALU2 | MO-T40005B | 0.1 mg |
| mAb anti-Human Lung Carcinoma, 3504 | MO-T40005C | 0.1 mg |
| mAb anti-Human Hepatocellular Carcinoma, CHALV1 | MO-T40006A | 0.1 mg |
| mAb anti-Human AFP, AFP-Y2, Detector | MO-T40007A | 0.1 mg |
| mAb anti-Human AFP, AFP-Y1, Capture | MO-T40007B | 0.1 mg |
| mAb anti-Human BPH, YBPH-1 | MO-T40008A | 0.1 mg |
| mAb anti-Human BPH, YBPH-2 | MO-T40008B | 0.1 mg |
| mAb anti-Human PML, B3E9 | MO-T40010A | 0.1 mg |
| mAb anti-Human PML, B4C8 | MO-T40010B | 0.1 mg |
| mAb anti-CA 125, 110 | MO-T40012A | 0.1 mg |
| mAb anti-CA 125, 76 | MO-T40012B | 0.1 mg |
| mAb anti-CA 125, 23 | MO-T40012C | 0.1 mg |
| mAb anti-CA 125, 15 | MO-T40012D | 0.1 mg |
| mAb anti-CA 125 | MO-T40012E | 0.1 mg |
| mAb anti-CA50, 93 | MO-T40014A | 0.1 mg |
| mAb anti-CA50, 826 | MO-T40014B | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,8E2 (Free Sample Available) | MO-T40015A | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,9B2 (Free Sample Available) | MO-T40015B | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,1A5 (Free Sample Available) | MO-T40015C | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,4E11 (Free Sample Available) | MO-T40015D | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,9E1 (Free Sample Available) | MO-T40015E | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,7C4 (Free Sample Available) | MO-T40015F | 0.1 mg |
| mAb anti- human carbohydrate antigen 19-9 (CA 19-9) ,7E6 (Free Sample Available) | MO-T40015G | 0.1 mg |
| mAb anti-Human Colorectal Carcinoma, Y94 | MO-T40022 | 0.1 mg |
| mAb anti-Human Colorectal Carcinoma/CD3, BS-1 | MO-T40035 | 0.1 mg |
| mAb anti-Human CEA, CEA-Y2, Detector | MO-T40051A | 0.1 mg |
| mAb anti-Human CEA, CEA-Y1, Capture | MO-T40051B | 0.1 mg |
| mAb anti-Human Free PSA, 103, Detector | MO-T40052A | 0.1 mg |
| mAb anti-Human Free PSA, 108, Capture | MO-T40052B | 0.1 mg |
| mAb anti-Human PSA, CHYH1, Capture | MO-T40081A | 0.1 mg |
| mAb anti-Human PSA, CHYH2, Dectector | MO-T40081B | 0.1 mg |
| mAb anti-Human PMA, YPMA-1 | MO-T40083A | 0.1 mg |
| mAb anti-Human PMA, YPMA-2 | MO-T40083B | 0.1 mg |
| mAb anti-Human PSP, YPSP-1 | MO-T40085A | 0.1 mg |
| mAb anti-Human PSP, YPSP-2 | MO-T40085B | 0.1 mg |
| mAb anti-Human PSP, YPSP-3 | MO-T40085C | 0.1 mg |
| mAb anti-Human PSP, YPSP-4 | MO-T40085D | 0.1 mg |
| mAb anti-Human PSMA, YPSMA-1 | MO-T40086A | 0.1 mg |
| mAb anti-Human PSMA, YPSMA-2 | MO-T40086B | 0.1 mg |
| mAb anti-Human PSMA, 4H11 | MO-T40086C | 0.1 mg |
| mAb anti-Human PSMA, 7F3 | MO-T40086D | 0.1 mg |
| mAb anti-Human PTMA, 8H12 | MO-T40087A | 0.1 mg |
| mAb anti-Human PTMA, 9A10 | MO-T40087B | 0.1 mg |
| mAb anti-Human PTMA, 6A3 | MO-T40087C | 0.1 mg |
| mAb anti-Human PTMA, 4G2 | MO-T40087D | 0.1 mg |
| mAb anti-Human PTMA, 5A10 | MO-T40087E | 0.1 mg |
| mAb anti-Human PTMA, 6H7 | MO-T40087F | 0.1 mg |
| mAb anti-Human PTMA, 1F2, Capture | MO-T40087G | 0.1 mg |
| mAb anti-Human PTMA, 4C3 | MO-T40087H | 0.1 mg |
| mAb anti-Human PTMA, 4A7, Detector | MO-T40087I | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 9A4 | MO-T40088A | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 2E6 | MO-T40088B | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 1A10 | MO-T40088C | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 5C2 | MO-T40088D | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 10H9 | MO-T40088E | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 2A3 | MO-T40088F | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 2E5 | MO-T40088G | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 5H12 | MO-T40088H | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 9C7 | MO-T40088I | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 9D5 | MO-T40088J | 0.1 mg |
| mAb anti-Human S100A7 (psoriasin), 3E7 | MO-T40088K | 0.1 mg |
| Human PSA ELISA Kit | EL10005 | 96 wells |
| Human IL-8 ELISA Kit | EL10008 | 96 wells |
| Human MCAF / MCP-1 ELISA Kit | EL10009 | 96 wells |
| Human EGF ELISA Kit | EL10010 | 96 wells |
| Human LH ELISA Kit | EL10011 | 96 wells |
| Human TSH ELISA Kit | EL10012 | 96 wells |
| Neonatal TSH ELISA Kit | EL10012N | 96 wells |
| Ultra-Sensitive Human TSH ELISA Kit | EL10012U | 96 wells |
| Human FSH ELISA Kit | EL10013 | 96 wells |
| Human Prolactin ELISA Kit | EL10014 | 96 wells |
| Human SAA ELISA Kit | EL10015 | 96 wells |
| Human SAA ELISA Kit (2nd Generation) | EL10015L | 96 wells |
| Human MCP-3 ELISA Kit | EL10016 | 96 wells |
| Human TNF-α ELISA Kit | EL10019 | 96 wells |
| Human GM-CSF ELISA Kit | EL10020 | 96 wells |
| Human IL-16 ELISA Kit | EL10021 | 96 wells |
| High Sensitivity Human CRP ELISA Kit | EL10022hs | 96 wells |
| Human IL-6 ELISA Kit | EL10023 | 96 wells |
| Human IFN-γ ELISA Kit | EL10024 | 96 wells |
| Human IL-2 ELISA Kit | EL10025 | 96 wells |
| Human IL-4 ELISA Kit | EL10026 | 96 wells |
| Human IL-10 ELISA Kit | EL10027 | 96 wells |
| Human IL-1β ELISA Kit | EL10028 | 96 wells |
| Human TGF-β1 ELISA Kit | EL10029 | 96 wells |
| Human Growth Hormone (hGH) ELISA Kit/Hormone Elisa | EL10030 | 96 wells |
| High Sensitivity Human Growth Hormone (H-hGH) ELISA Kit | EL10030H | 96 wells |
| Human Chorionic Gonadotropin (hCG) ELISA Kit | EL10031 | 96 wells |
| Human IL-12 (P70) ELISA Kit | EL10032 | 96 wells |
| Human IL-2 sRα ELISA Kit | EL10033 | 96 wells |
| Human IL-6 sR ELISA Kit | EL10034 | 96 wells |
| Human IL-5 ELISA Kit | EL10035 | 96 wells |
| HAMA ELISA Kit | EL10036 | 96 wells |
| Human IL-13 Rα2 ELISA Kit | EL10039 | 96 wells |
| Human IL-1α ELISA Kit | EL10040 | 96 wells |
| Human IL-7 ELISA Kit | EL10041 | 96 wells |
| Human IL-11 ELISA Kit | EL10042 | 96 wells |
| Human IL-15 ELISA Kit | EL10044 | 96 wells |
| Human M-CSF ELISA Kit | EL10046 | 96 wells |
| Human TNF-β ELISA Kit | EL10047 | 96 wells |
| Human bFGF ELISA Kit | EL10048 | 96 wells |
| Human Alphafetoprotein (AFP) ELISA Kit | EL10049 | 96 wells |
| Human B2MG ELISA Kit | EL10051 | 96 wells |
| Human Carcinoembryonic Antigen (CEA) ELISA Kit | EL10052 | 96 wells |
| Human IL-17A ELISA Kit | EL10053 | 96 wells |
| Human IL-13 ELISA Kit | EL10054 | 96 wells |
| Human IL-22 ELISA Kit | EL10055 | 96 wells |
| Human IL-9 ELISA Kit | EL10056 | 96 wells |
| Human Amyloid Beta Peptide 42 ELISA Kit | EL10057 | 96 wells |
| Human Programmed Death-Ligand 1 (PD-L1) ELISA Kit | EL10058 | 96 wells |
| Human Programmed Death-1 (PD-1) ELISA Kit | EL10059 | 96 wells |
| Human IL-18 ELISA Kit | EL10060 | 96 wells |
| Multiplex Human Cytokine ELISA Kit (Inflammatory) | EM10001 | 96 wells |
| Multiplex Human Cytokine ELISA Kit (M1/M2/MDSC Cytokines) | EM10002 | 96 wells |
| Multiplex Human Cytokine ELISA Kit (Th1/Th2/Th17) | EM10003 | 96 wells |
| Mouse IL-17A ELISA Kit | MEC1001 | 96 wells |
| Mouse IFN-γ ELISA Kit | MEC1002 | 96 wells |
| Mouse TNF-α ELISA Kit | MEC1003 | 96 wells |
| Mouse GM-CSF ELISA Kit | MEC1004 | 96 wells |
| Mouse MCP-1 ELISA Kit | MEC1005 | 96 wells |
| Mouse IL-2 ELISA Kit | MEC1006 | 96 wells |
| Mouse IL-5 ELISA Kit | MEC1007 | 96 wells |
| Mouse IL-6 ELISA Kit | MEC1008 | 96 wells |
| Mouse IL-4 ELISA Kit | MEC1009 | 96 wells |
| Mouse IL-1β ELISA Kit | MEC1010 | 96 wells |
| Mouse IL-1α ELISA Kit | MEC1011 | 96 wells |
| Mouse TGF-β1 ELISA Kit | MEC1012 | 96 wells |
| pAb anti-Human CRP, Tracer (HRP Labeled) | AI20009P | 0.2 mL |
| mAb anti-Human TNF-α, CH8820, Capture | MO-C40003B | 0.1 mg |
| mAb anti-Human TNF-α, B1E4, Detector | MO-C40003E | 0.1 mg |
| mAb anti-Human TNF-α, B1E4, Tracer (HRP Labeled) | MO-C40003T | 0.2 mL |
| mAb anti-Human TNF-α, B1E4, Tracer (Biotin Labeled) | MO-C40003TB | 0.1 mL |
| mAb anti-Human IL-8, I8-S2, Capture | MO-C40017A | 0.1 mg |
| mAb anti-Human IL-8, I8-60, Detector | MO-C40017D | 0.1 mg |
| mAb anti-Human IL-8, I8-60, Tracer (HRP Labeled) | MO-C40017T | 0.2 mL |
| mAb anti-Human IL-8, I8-60, Tracer (Biotin Labeled) | MO-C40017TB | 0.1 mL |
| mAb anti-Human MCP-1, S14, Capture | MO-C40021B | 0.1 mg |
| mAb anti-Human MCP-1, S101, Detector | MO-C40021D | 0.1 mg |
| mAb anti-Human MCP-1, S101, Tracer (HRP Labeled) | MO-C40021T | 0.2 mL |
| mAb anti-Human MCP-1, S101, Tracer (Biotin Labeled) | MO-C40021TB | 0.1 mL |
| mAb anti-Human SAA, 115, Capture | MO-C40028A | 0.1 mg |
| mAb anti-Human SAA, 607, Detector | MO-C40028E | 0.1 mg |
| mAb anti-Human SAA, 607, Tracer (HRP Labeled), 0.2mL | MO-C40028T | 0.2 mL |
| mAb anti-Human SAA, 607, Tracer (Biotin Labeled), 0.1mL | MO-C40028TB | 0.1 mL |
| mAb anti-Human EGF, S-134, Capture | MO-C40044D | 0.1 mg |
| mAb anti-Human EGF, S-146, Detector | MO-C40044F | 0.1 mg |
| mAb anti-Human EGF, S-146, Tracer (HRP Labeled) | MO-C40044T | 0.2 mL |
| mAb anti-Human EGF, S-146, Tracer (Biotin Labeled) | MO-C40044TB | 0.1 mL |
| mAb anti-Human MCP-3, 113, Detector | MO-C40088A | 0.1 mg |
| mAb anti-Human MCP-3, 542, Capture | MO-C40088G | 0.1 mg |
| mAb anti-Human MCP-3, 113, Tracer (HRP Labeled) | MO-C40088T | 0.2 mL |
| mAb anti-Human MCP-3, 113, Tracer (Biotin Labeled) | MO-C40088TB | 0.1 mL |
| mAb anti-Human IL-16, 323, Detector | MO-C40089J | 0.1 mg |
| mAb anti-Human IL-16, 398, Capture | MO-C40089K | 0.1 mg |
| mAb anti-Human IL-16, 323, Tracer (HRP Labeled) | MO-C40089T | 0.2 mL |
| mAb anti-Human GM-CSF, 59, Capture | MO-C40090B | 0.1 mg |
| mAb anti-Human GM-CSF, 429, Detector | MO-C40090D | 0.1 mg |
| mAb anti-Human GM-CSF, 429, Tracer (HRP Labeled) | MO-C40090T | 0.2 mL |
| mAb anti-Human GM-CSF, 429, Tracer (Biotin Labeled) | MO-C40090TB | 0.1 mL |
| mAb anti Human IL-18 clone 2A10, Capture | MO-C40094A | 0.1mg |
| mAb anti Human IL-18 clone 10H4, Detector | MO-C40094B | 0.1mg |
| mAb anti human IL-18 clone 10H4, Tracer (Biotin Labeled) | MO-C40094TB | 0.1 mL |
| mAb anti Human IL-15 clone 5E8, Capture | MO-C40095A | 0.1mg |
| mAb anti Human IL-15 clone B1H6, Detector | MO-C40095B | 0.1mg |
| mAb anti human IL-15 clone B1H6, Tracer (Biotin labeled) | MO-C40095TB | 0.1 mL |
| mAb anti-HIV-1 P24 (Core Protein), 473, Detector | MO-I40002A | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 340, Capture | MO-I40002D2 | 0.1 mg |
| mAb anti-HIV-1 P24 (Core Protein), 473, Tracer (HRP), 0.2 mL | MO-I40002T2 | 0.2 mL |
| mAb anti-Human PD-1 / CD279, 7G12, Tracer (Biotin labeled) | MO-L40043TB | 0.1 mL |
| mAb anti Human PD-L1 clone 12B4, Detector | MO-L40044I | 0.1 mg |
| mAb anti Human PD-L1 clone 15G3, Capture | MO-L40044N | 0.1 mg |
| mAb anti human PD-L1 clone 12B4, Tracer (Biotin Labeled) | MO-L40044TB | 0.1 mL |
| mAb anti-hGH, YC6, Capture | MO-M40012A | 0.1 mg |
| mAb anti-hGH, YC8, Tracer (HRP Labeled), 0.2 mL | MO-M40012T | 0.2 mL |
| mAb anti-hGH, YC8, Tracer (Biotin Labeled), 0.1 mL | MO-M40012TB | 0.1 mL |
| mAb anti-Human B2MG, D2E9, Capture | MO-M40021C | 0.1 mg |
| mAb anti-Human B2MG, D3A2, Detector | MO-M40021F | 0.1 mg |
| mAb anti-Human B2MG, D3A2, Tracer (HRP Labeled), 0.2mL | MO-M40021T | 0.2 mL |
| mAb anti-human CRP, 63F4, Capture | MO-M40023A | 0.1 mg |
| mAb anti-human TSH, TSH-2, Detector | MO-M40046A | 0.1 mg |
| mAb anti-human TSH, TSH-1, Capture | MO-M40046B | 0.1 mg |
| mAb anti-human TSH, TSH-2, Tracer (HRP Labeled), 0.2 mL | MO-M40046T | 0.2 mL |
| mAb anti-Human Prolactin, PRL-1, Capture | MO-M40047B | 0.5 mg |
| mAb anti-Human Prolactin, PRL-2, Tracer (HRP Labeled), 0.2 mL | MO-M40047T | 0.2 mL |
| mAb anti-Human LH, LH-1, Capture | MO-M40048B | 0.5 mg |
| mAb anti-Human LH, LH-2, Tracer (HRP Labeled), 0.2 mL | MO-M40048T | 0.2 mL |
| mAb anti-hCG, HCG-1, Capture | MO-M40049B | 0.5 mg |
| mAb anti-hCG, HCG-2, Tracer (HRP Labeled), 0.2 mL | MO-M40049T | 0.2 mL |
| mAb anti-Human FSH, FSH-1, Capture | MO-M40050B | 0.5 mg |
| mAb anti-Human FSH, FSH-2, Tracer (HRP Labeled) | MO-M40050T | 0.2 mL |
| mAb anti-Amyloid β Peptide 42, CA9 10C11, Detector | MO-M40093B | 0.5 mg |
| mAb anti-Amyloid β Peptide 42, CA9 10C11, Tracer (Biotin) | MO-M40093TB | 0.1 mL |
| mAb anti-Amyloid β Peptide N-terminal, NT 5B8, Capture | MO-M40094D | 0.5 mg |
| mAb anti-Amyloid β Peptide 40, CV9 7B10, Detector | MO-M40095A | 0.1 mg |
| mAb anti-Amyloid β Peptide 40, CV9 7B10, Tracer (Biotin) | MO-M40095TB | 0.1 mL |
| mAb anti-Human AFP, AFP-Y2, Detector | MO-T40007A | 0.1 mg |
| mAb anti-Human AFP, AFP-Y1, Capture | MO-T40007B | 0.1 mg |
| mAb anti-Human AFP, AFP-2, Tracer (HRP Labeled), 0.2 mL | MO-T40007T | 0.2 mL |
| mAb anti-Human CEA, CEA-Y2, Detector | MO-T40051A | 0.1 mg |
| mAb anti-Human CEA, CEA-Y1, Capture | MO-T40051B | 0.1 mg |
| mAb anti-Human CEA, CEA-Y2, Tracer (HRP Labeled), 0.2 mL | MO-T40051T | 0.2 mL |
| mAb anti-Human Free PSA, 103, Detector | MO-T40052A | 0.1 mg |
| mAb anti-Human Free PSA, 108, Capture | MO-T40052B | 0.1 mg |
| mAb anti-Human Free PSA, 103, Tracer (HRP Labeled), 0.2 mL | MO-T40052T | 0.2 mL |
| mAb anti-Human PSA, CHYH1, Capture | MO-T40081A | 0.1 mg |
| mAb anti-Human PSA, CHYH2, Dectector | MO-T40081B | 0.1 mg |
| mAb anti-Human PSA, CHYH2, Tracer (HRP Labeled), 0.2 mL | MO-T40081T | 0.2 mL |
| Human Chorionic Gonadotrophin (hCG), 10 mg | AP30002 | 10 mg |
| Human Immunoglobulin G (IgG), 10 mg | IG30001 | 10 mg |
| Mouse Immunoglobulin G (IgG), 10 mg | IG41002 | 10 mg |
| Mouse Immunoglobulin G2b (IgG2b), 10 mg | IG41004 | 10 mg |
| Rat Immunoglobulin G (IgG) | IG42003 | 10 mg |
| Human Umbilical Cord Serum, 10 mL | S30010 | 10 mL |
| ELISA Coating (EC) Stabilizer, 500 mL | S7001 | 500 mL |
| Human IL-8 Matched Antibody Pair for ELISpot | SL10008A | 5 × 96 wells |
| Human IL-8 Development Set for ELISpot | SL10008B | 5 × 96 wells |
| Human IL-8 ELISpot Kit | SL10008E | 6 X 96 wells |
| Human MCAF (MCP-1) Matched Antibody Pair for ELISpot | SL10009A | 5 × 96 wells |
| Human MCAF (MCP-1) Development Set for ELISpot | SL10009B | 5 × 96 wells |
| Human MCAF (MCP-1) ELISpot Kit | SL10009E | 6 X 96 wells |
| Human GM-CSF Matched Antibody Pair for ELISpot | SL10020A | 5 × 96 wells |
| Human GM-CSF Development Set for ELISpot | SL10020B | 5 × 96 wells |
| Human GM-CSF ELISpot Kit | SL10020E | 6 X 96 wells |
| Human IFN-γ Matched Antibody Pair for ELISpot | SL10024A | 5 × 96 wells |
| Human IFN-γ Development Set for ELISpot | SL10024B | 5 × 96 wells |
| Human IFN-γ ELISpot Kit | SL10024E | 6 X 96 wells |
| Human IL-12 (P70) ELISpot Kit | SL10032E | 6 X 96 wells |
| TMB Solution (500 mL Part A & 500 mL Part B) | SU6006 | 1.0 L |
| pAb Rabbit anti-HCV Virus, 1.0 mg | AI20006P | 1.0 mg |
| pAb Rabbit anti-HIV-1 p24, 1.0 mg | AI20008P | 1.0 mg |
| pAb anti-Human CRP, Tracer (HRP Labeled) | AI20009P | 0.2 mL |
| pAb Rabbit anti-Mouse IgG , 1.0 mg | AI50005 | 1.0 mg |
| pAb Rabbit anti-Mouse IgG - HRP Conjugated, 1.0 mL | AI50005P | 1.0 mL |
| pAb Rabbit anti-hGH, | AI50006P | 1.0 mg |
| pAb Chicken anti-human IL-8 (IgY fraction) | AI60001 | 1.0 mg |
| pAb Rabbit anti-Human FPRL-1 2nd Extracellular Loop | AI70001A | 0.1 mg |
| pAb Rabbit anti-Human FPRL-1 C-terminal | AI70001B | 0.1 mg |
| pAb Rabbit anti-Human PML [Ring Finger Domain] | AI70002A | 0.1 mg |
| pAb Rabbit anti-Human PML [B-box 1 domain] | AI70002B | 0.1 mg |
| pAb Rabbit anti-Bcl-2 | AI70003A | 0.1 mg |
| pAb Rabbit anti-Phospho-Bcl-2 (Thr56) | AI70003B | 0.1 mg |
| pAb Rabbit anti-Phospho-Bcl-xL (Thr115) | AI70003D | 0.1 mg |
| pAb Rabbit anti-Phospho c-kit (Tyr719) | AI70004A | 0.1 mg |
| pAb Rabbit anti-Phospho IKK-γ (Ser31) | AI70005A | 0.1 mg |
| pAb Rabbit anti-NF-κB-p65 (RelA) | AI70006A | 0.1 mg |
| pAb Rabbit anti-Phospho-NF-қB-p65 (Ser276) | AI70007A | 0.1 mg |
| pAb Rabbit anti-Phospho-NF-қB-p65 (Ser468) | AI70008A | 0.1 mg |
| pAb Rabbit anti-Phospho NF-қB-p105/p50 (Ser337) | AI70009A | 0.1 mg |
| pAb Rabbit anti-Human Serum Albumin (HSA) | AI80001 | 0.1 mg |
| pAb Rabbit anti-Human Fibrinogen, 0.1 mg | AI80002 | 0.1 mg |
| pAb Rabbit anti-Human Transferrin | AI80003 | 0.1 mg |
| pAb Rabbit anti-Human IgA, 0.5 mg | AI80004 | 0.5 mg |
| pAb Rabbit anti-human IgM, 0.5 mg | AI80005 | 0.5 mg |
| pAb Rabbit anti-Human TREK-1 (K2p2.1) | AI80006A | 0.1 mg |
| pAb Rabbit anti-Mouse Kchip1 | AI80007 | 0.1 mg |
| pAb Rabbit anti-Mouse Kchip4 | AI80008 | 0.1 mg |
| pAb Rabbit anti-Mouse Kv4.3 | AI80010A | 0.1 mg |
| pAb Rabbit anti-Mouse TRPV1 | AI80011A | 0.1 mg |
| pAb Rabbit anti-Mouse TRPV3 | AI80012A | 0.1 mg |
| pAb Rabbit anti-Human JAK2 | AI80013A | 0.1 mg |
| pAb Rabbit anti-Human Glutathione S Transferase (GST), 0.1 mg | AI80014 | 0.1 mg |
| pAb Rabbit anti-Human Amyloid beta peptide 42 | AI90001 | 0.1 mg |
| pAb Rabbit anti-Human Amyloid beta peptide 43 | AI90002 | 0.1 mg |

ProteinMods公司位于美国,是定制蛋白、抗体及生物化学分子产品的的供应商。
ProteinMods is a US based manufacter of custom proteins, antibodies and biomolecules. We strive to provide high quality and reliable products for your lab. ProteinMods is headed by Joe Beck, PhD. He is a versatile PhD. cell biologist with postdoctoral training in analytical chemistry and multiple years experience in drug development. Joe has a diverse background as evidenced by accomplishments in pharmacology, protein chemistry, neuroscience, surface chemistry, and nanotechnology. His mission is to lead a company in the production of top quality proteins and antibodies for researchers across the country and internationally. Joe also participates in many other ventures related to the biochemistry industry forging a path of research and has contributed as an author on many different publications.
PROTEINMODS的主要产品包括:
Antibody
Biosensing
Flow Cytometry
Fluorescent Microscopy
Immunodepletion
Immunohistochemistry
Immunoprecipitation
Protease Assays
Protein Crosslinking
Western Blotting
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

R&D Systems位于美国的明尼苏达州,一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1977年,公司推出第一个产品--富血小板血浆质控品;1981年,公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中,R&D Systems仍持续开发各种血控品产品。
1985年,作为公司推出的第一个科研试剂产品,也是全球第一家将该产品进行商业化生产的产品,R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子,TGF-beta1蛋白在多种细胞中进行表达,并作为胞外信号分子参与免疫功能,细胞增殖和细胞分化等生物学过程。该产品推出后,公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。天然蛋白类产品的成功推广,加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部(现Biotechnology事业部)。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较,DNA重组技术生产的蛋白产品其成本更低,产量更高,完全摆脱原料的限制。1989年,Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体,并于1990年开发了第一个ELISA试剂盒。
R&D System的主要产品包括:
Recombinant Proteins
GMP Proteins
Antibodies
ELISAs
Luminex Assays & High Performance Assays
Stem Cell Products
Cell Culture
Small Molecules & Peptides
Enzymes
ELISpots
cDNA Clones
Flow Cytometry Workflow Solutions
Proteome Profiler Antibody Arrays
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://haemtech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="R&D System"> R&D System
Stemmera公司位于美国加州,主要生产干细胞相关产品,包括检测试剂盒、培养基、抗体、缓冲液,还包括用于干细胞研究的细胞系。
Stemmera Inc is a privately owned biotechnology company located in Bay Area, California that focus in developing innovative technology and application solution for stem cell research. Our products include kit, culture medium, reagents, antibodies, buffer and solution, cell lines that are convenient tools used in stem cell research.
Stemmera公司主要产品:
(1)Kit
Alkaline Phosphatase (AP) Detection Kit (Ready-to-use)-Blue
Alkaline Phosphatase (AP) Detection Kit (Ready-to-use)-Red
Human Fibroblast (hFIB) Reprogramming Kit
Human Blood Cell (hBLD) Reprogramming Kit
(2)Media
Human ESCs/iPSCs Serum-/ Feeder-Free Medium (hStemSFM)
Human ESCs/iPSCs Xeno-Free Medium (hStemXFM)
Human Fibroblast (hFIB) Reprogramming Medium
Human Blood Cell (hBLD) Reprogramming Medium
Fibroblast Growth Medium
(3)Buffer & Solutions
Non-Enzymatic Cell Dissociation Solution (1X)
Serum-Free Cryopreservation Solution for Human ESCs/iPSCs
0.2% Gelatin
0.1% Gelatin
Universal Cryopreservation Solution
Blood Cell Cryopreservation Solution (1x)
Cell Fixation Solution (4% Paraformaldehyde, PFA)
Cell Fixation Solution (10% Formalin)
Metaphase Arrest Solution (10 μg/ml, 10X)
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://haemtech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Stemmera"> Stemmera
<艾美捷科技代理Nanosoftpolymers品牌全系列产品
Nanosoft Polymers(NSP)是一家专注于提供用于治疗、设备和诊断的即用型功能化聚合物和共聚物的企业,旨在弥合聚合物和药物递送之间的差距。NSP生产和销售一系列独特的功能性聚合物、共聚物和聚合物偶联物,其聚合物目录丰富多样,涵盖功能性PLGA - PEG、PLA - PEG、PCL - PEG、脂质PEG、聚(L - 赖氨酸)- PEG、聚(L - 谷氨酸)- PEG和聚乙二醇化试剂等。这些产品可应用于药物/基因递送、封装、细胞粘附和表面修饰等多个研究领域。除了销售现有产品,NSP还专门从事聚合物合成和功能化、纳米颗粒制造、表面改性以及具有广泛分子量范围的反应性低聚物和聚合物的定制合成,能够满足客户多样化的需求。

▍Nanosoftpolymers产品线
● 多糖:是由长链单糖单元通过糖苷键连接而成的高分子碳水化合物,具有良好的生物相容性、无毒性和非免疫原性。
● 抗癌试剂与原料药:提供种类丰富的高品质抗癌试剂与原料药,用于药物研发。
● 脂质:NSP的功能性脂质用于制备脂质体或纳米颗粒,这些脂质体或纳米颗粒可通过脂质头部的官能团进一步进行生物偶联修饰。
● PEI-PEGs:NSP 的 PEI-PEG 聚合物包括 PEG 接枝的支链 PEI和 PEG 偶联的线性PEI,可用于体外和体内将寡核苷酸递送至细胞和组织。
● 聚氨基酸:可提高药物结合物的溶解度和稳定性、药物包封、药物靶向、绕过多药耐药因素、对免疫系统的刺激极小、低毒性以及生物可降解性。
● 脂质 - 聚乙二醇(Lipid-PEGs):提供多样化的脂质及磷脂PEG衍生物,广泛应用于药物递送、脂质体 / 胶束形成、小分子和大分子药物制剂以及表面修饰等领域。
● Poly(amino acid)-PEGs:NSP 的 PEG-PAA 包括聚(L - 赖氨酸)-PEG、聚(L - 谷氨酸)-PEG、聚(L - 天冬氨酸)-PEG 及其功能化共聚物。
● 功能性聚乙二醇:提供多种高品质 PEG 试剂,用于聚乙二醇化、药物递送、生物偶联和表面修饰。NSP 的功能性聚乙二醇包括单线性聚乙二醇、同源双功能聚乙二醇、异源双功能聚乙二醇和多臂聚乙二醇。
● 单体:是一种可通过化学方式或超分子方式与其他分子结合,从而形成(超分子)聚合物的分子。
● 聚酯 - 聚乙二醇(Polyester-PEGs):提供基于聚酯的功能性两亲性嵌段共聚物,如聚乳酸 - 聚乙二醇(PLA-PEG)、聚乳酸 - 羟基乙酸共聚物 - 聚乙二醇(PLGA-PEG)、聚己内酯 - 聚乙二醇(PCL-PEG),用于药物递送研究。
● 按官能团分类的聚合物:包括但不限于:胺基、Boc 或 Fmoc 保护的胺基、羧基、马来酰亚胺基、生物素、叠氮基、巯基、酰肼基、炔基、邻吡啶二硫基(OPSS)、活性琥珀酸酯基、乙烯基砜基(VS)、丙烯酸酯基、硝基苯基碳酸酯基(NPC)、二苯并环辛炔基(DBCO)、叶酸基等。
● 荧光聚合物:提供 “即开即用型” 荧光聚合物,研究人员可借助显微镜或 IVIS 成像技术对聚合物及纳米药物进行追踪。NSP的荧光染料包括罗丹明、荧光素、Cy3、Cy5.0、Cy5.5 及 Cy7 等。
▍Nanosoftpolymers部分产品列表
| 品名 | 货号 | 分子量 | 规格 |
| Hyaluronate Amine | 13390 | 5K, 10K, 50 K, 100 K, 1000 K, 1500 K | 100mg, 1g |
| Hyaluronate Thiol | 24656 | 5K, 10K, 50 K, 100 K, 1000 K, 1500 K | 100mg, 1g |
| Hyaluronic Acid Tetrabutylammonium | 13378 | 50 K, 100 K, 1000 K, 1500 K | 100mg, 1g |
| Methacrylated Hyaluronic Acid (HA-MA) | 13204 | 50 K, 100 K, 1000 K, 1500 K | 100mg, 1g |
| 10-Hydroxycamptothecin | 11999 | 364.35 | 100mg, 500mg, 1g, 5g, 10g |
| 7-Ethyl-10-hydroxycamptothecin | 12007 | 392.4 | 20mg, 100mg, 500mg, 1g |
| Abarelix Acetate | 12014 | 1416.08 | 1mg, 5mg, 10mg, 25mg, 50mg, 100mg |
| Camptothecin | 11992 | 348.35 | 250mg, 500mg, 1g, 5g |
| Cisplatin | 12032 | 300.05 | 100mg, 200mg, 500mg, 1g |
| Cucurbitacin B | 11964 | 558.712 | 5mg, 10mg, 20mg, 50mg, 100mg |
| Cucurbitacin E | 12024 | 556.696 | 1mg, 5mg, 10mg, 25mg |
| Cyclosporine A | 12086 | 1202.61124 | 100mg, 500mg, 1g, 5g, 10g |
| Doxorubicin hydrochloride | 11947 | 579.98 | 50mg, 100mg, 500mg, 1g |
| Irinotecan HCl | 11985 | 677.18 | 20mg, 50mg, 100mg, 500mg |
| Paclitaxel | 11955 | 853.33096 | 50mg, 100mg, 1g, 10g, bulk |
| Topotecan Hydrochloride | 11977 | 457.91 | 20mg, 50mg, 100mg, 500mg |
| β-Lapachone | 12048 | 242.09429 | 10mg, 25mg, 100mg |
| ALC-0315 | 28068 | 766.290 | 50mg, 100mg, 200mg, 1g |
| DLin-KC2-DMA | 27581 | 642.11 | 5mg, 10mg, 25mg, 50mg, 100mg, 200mg |
| DLin-MC3-DMA | 25325 | 642.11 | 50mg, 100mg, 1g, 5g |
| DODAP (18:1) | 26495 | 648.05 | 100mg, 500mg, 1g |
| DODMA | 27967 | 620.104 | 50mg, 100mg, 1g |
| DOTAP (18:1) | 25396 | 698.555 | 100mg, 500mg, 1g |
| DOTMA | 25335 | 670.575 | 50mg, 100mg, 1g |
| DSTAP (18:0) | 26129 | 702.57 | 100mg, 500mg, 1g |
| SM-102 | 27852 | 709.66 | 50mg, 100mg, 200mg, 1g |
| ALC-0315 | 28068 | 766.290 | 50mg, 100mg, 200mg, 1g |
| DLin-KC2-DMA | 27581 | 642.11 | 5mg, 10mg, 25mg, 50mg, 100mg, 200mg |
| DSPC (18:0 PC) | 26737 | 790.145 | 500mg, 1g, 5g |
| DSPE | 13903 | 748.07 | 100mg, 200mg, 500mg, 1g |
| DSPE-Maleimide/DSPE-MAL | 10791 | 898.19 | 50mg, 100mg, 500mg |
| DSTAP (18:0) | 26129 | 702.57 | 100mg, 500mg, 1g |
| SM-102 | 28527 | 709.66 | 50mg, 100mg, 200mg, 1g |

Lunginnov公司位于法国里尔市,主要产品线包括生命科学试剂和体外诊断医疗器械。Lunginnov公司最大的特色是为研究者提供Endocan和CG-Cleaved Endocan检测产品(包括抗体、ELISA试剂盒、重组蛋白等),这两个分子已经被证明是肺部感染/损伤的标志分子。
Lunginnov develops innovative solutions for respiratory diseases that enable earlier therapeutic decision to be helpful for patients. Lunginnov markets 2 product lines:
A range of unique reagents for research in Life Sciences
A range of original medical devices for In Vitro Diagnostic
Lunginnov is declared manufacturer to the french regulatory agency ANSM. The company devotes a significant part of its budget to its internal R&D and to set up collaborative projects with Research Centers in France and abroad. Lunginnov is specialized on endocan and CG-cleaved endocan as markers of lung infection/injury, by proposing specific tools of high quality researchers and clinicians.
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172431432
传真:18327026838
邮箱:sales@amyjet.com
0.3445